Literature DB >> 8658372

Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects.

S Nasser1, P E Christie, R Pfister, A R Sousa, A Walls, M Schmitz-Schumann, T H Lee.   

Abstract

BACKGROUND: The aspirin-induced bronchoconstriction in patients with aspirin-sensitive asthma is caused by cysteinyl leukotriene release. The cellular source of the leukotrienes is unknown. The inflammatory cell infiltrate in bronchial biopsy samples from seven aspirin-sensitive asthmatic (ASA) subjects and eight non-ASA subjects before and after local challenge with lysine aspirin was therefore examined.
METHODS: Using flexible bronchoscopy, airway mucosal biopsy samples were taken and lysine aspirin solution was placed directly onto a carina of the contralateral lung. Twenty minutes later a second series of biopsy samples was taken from the site of the local endobronchial lysine aspirin challenge. The biopsy samples were double immunostained with a rabbit polyclonal antibody to the enzyme 5-lipoxygenase and monoclonal antibodies to mast cells (AA1), neutrophils (NP57), macrophages (EBM11), T lymphocytes (anti-CD3), and total (BMK13) and activated eosinophils (EG2).
RESULTS: A decrease in both absolute mast cell numbers staining with mast cell tryptase (AA1) and the percentage of mast cells co-immunostaining with 5-lipoxygenase was seen in the ASA patients after lysine aspirin challenge compared with the non-ASA control group. There was also an increase in the numbers of activated eosinophils (EG2) in the ASA subjects compared with the non-ASA group. No changes were observed in the total numbers of macrophages (EBM11), neutrophils (NP57), total eosinophils (BMK13), and T lymphocytes (anti-CD3) after challenge with lysine aspirin.
CONCLUSIONS: The decrease in numbers of mast cells staining for tryptase and the increase in activated eosinophils after endobronchial challenge with lysine aspirin may represent degranulation of these cell types, and may be an early event associated with aspirin-sensitive reactions in ASA subjects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8658372      PMCID: PMC472802          DOI: 10.1136/thx.51.1.64

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  [Sodium cromoglycate nebulized solution has an acute bronchodilative effect in patients with aspirin-intolerant asthma (AIA)].

Authors:  S Imokawa; A Sato; M Taniguchi; M Toyoshima; K Nakazawa; H Hayakawa; K Chida
Journal:  Arerugi       Date:  1992-10

2.  Tryptase and histamine release during aspirin-induced respiratory reactions.

Authors:  J V Bosso; L B Schwartz; D D Stevenson
Journal:  J Allergy Clin Immunol       Date:  1991-12       Impact factor: 10.793

3.  3-Aminopropyltriethoxysilane (APES): a new advance in section adhesion.

Authors:  P H Maddox; D Jenkins
Journal:  J Clin Pathol       Date:  1987-10       Impact factor: 3.411

4.  Etiology of nasal polyps associated with aspirin-sensitive asthma.

Authors:  T Yamashita; H Tsuji; N Maeda; K Tomoda; T Kumazawa
Journal:  Rhinol Suppl       Date:  1989

5.  The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma.

Authors:  P E Christie; C M Smith; T H Lee
Journal:  Am Rev Respir Dis       Date:  1991-10

6.  Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects.

Authors:  P E Christie; P Tagari; A W Ford-Hutchinson; C Black; A Markendorf; M Schmitz-Schumann; T H Lee
Journal:  Am Rev Respir Dis       Date:  1992-12

7.  Study of mediators of anaphylaxis in nasal wash fluids after aspirin and sodium metabisulfite nasal provocation in intolerant rhinitic patients.

Authors:  C Ortolani; C Mirone; A Fontana; G C Folco; A Miadonna; N Montalbetti; M Rinaldi; A Sala; A Tedeschi; D Valente
Journal:  Ann Allergy       Date:  1987-11

8.  The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.

Authors:  B Dahlén; M Kumlin; D J Margolskee; C Larsson; H Blomqvist; V C Williams; O Zetterström; S E Dahlén
Journal:  Eur Respir J       Date:  1993-07       Impact factor: 16.671

9.  Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma.

Authors:  K Sladek; A Szczeklik
Journal:  Eur Respir J       Date:  1993-03       Impact factor: 16.671

10.  Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin.

Authors:  N R Ferreri; W C Howland; D D Stevenson; H L Spiegelberg
Journal:  Am Rev Respir Dis       Date:  1988-04
View more
  13 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

Review 2.  Severe rhinosinusitis.

Authors:  Rosemary Hallett; Stanley M Naguwa
Journal:  Clin Rev Allergy Immunol       Date:  2003-10       Impact factor: 8.667

Review 3.  Safety considerations in treating concomitant diseases in patients with asthma.

Authors:  L W Hunt
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

4.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

5.  Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes.

Authors:  Tanya M Laidlaw; Molly S Kidder; Neil Bhattacharyya; Wei Xing; Shiliang Shen; Ginger L Milne; Mariana C Castells; Heng Chhay; Joshua A Boyce
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

Review 6.  Aspirin-exacerbated respiratory disease and current treatment modalities.

Authors:  Emine Güven Sakalar; Nuray Bayar Muluk; Murat Kar; Cemal Cingi
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-18       Impact factor: 2.503

Review 7.  Pathogenesis of aspirin-exacerbated respiratory disease.

Authors:  Donald D Stevenson; Bruce L Zuraw
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

8.  Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics.

Authors:  Jong Sook Park; An Soo Jang; Sung Woo Park; Young Mok Lee; Soo Taek Uh; Yong Hoon Kim; Ji Yean Cha; Se Min Park; Choon-Sik Park
Journal:  Allergy Asthma Immunol Res       Date:  2009-12-30       Impact factor: 5.764

9.  Aspirin-exacerbated asthma.

Authors:  Mathew Varghese; Richard F Lockey
Journal:  Allergy Asthma Clin Immunol       Date:  2008-06-15       Impact factor: 3.406

10.  Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease.

Authors:  Ayse Aktas; Emel Kurt; Zafer Gulbas
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.